Clinical TrialsAbivax’s Obefazimod Meets All Phase 3 Endpoints in Ulcerative Colitis Abivax’s Obefazimod Meets All Phase 3 Endpoints in Ulcerative Colitis Read Post »
Health TidingsVera’s Atacicept Heads Toward Full Approval After FDA Aligns on Earli... Vera’s Atacicept Heads Toward Full Approval After FDA Aligns on Earli... Read Post »
Health TidingsLantern Reports Durable LP-300 Responses in EGFR L858R Lung Cancer Lantern Reports Durable LP-300 Responses in EGFR L858R Lung Cancer Read Post »
Health TidingsRoche’s Giredestrant Wins FDA Priority Review for Early Breast Cancer Roche’s Giredestrant Wins FDA Priority Review for Early Breast Cancer Read Post »
Clinical TrialsIDEAYA Scores Registrational Win for Darovasertib in Metastatic Uveal Melan... IDEAYA Scores Registrational Win for Darovasertib in Metastatic Uveal Melan... Read Post »
Clinical TrialsAstraZeneca’s Camizestrant Extends Progression-Free Survival in SERENA-6 AstraZeneca’s Camizestrant Extends Progression-Free Survival in SERENA-6 Read Post »
Clinical TrialsIza-bren Extends Survival in Phase 3 Trials Across Triple-Negative Breast a... Iza-bren Extends Survival in Phase 3 Trials Across Triple-Negative Breast a... Read Post »
Clinical TrialsEntrada Advances ENTR-601-45 to Higher Dose Cohort in DMD Entrada Advances ENTR-601-45 to Higher Dose Cohort in DMD Read Post »
New Drug ApprovalAbbVie Secures EU Approval for AQUIPTA in Acute Migraine AbbVie Secures EU Approval for AQUIPTA in Acute Migraine Read Post »
Health Tidings Mergers & AcquisitionsCEPI Backs Moderna’s Bundibugyo Ebola Vaccine with $50 Million CEPI Backs Moderna’s Bundibugyo Ebola Vaccine with $50 Million Read Post »
Health TidingsFDA Accepts Vertex’s Povetacicept After Strong Phase 3 IgAN Results FDA Accepts Vertex’s Povetacicept After Strong Phase 3 IgAN Results Read Post »
New Drug ApprovalAmgen Wins EU Approval for IMDYLLTRA in Relapsed ES-SCLC Amgen Wins EU Approval for IMDYLLTRA in Relapsed ES-SCLC Read Post »
Health Tidings Mergers & AcquisitionsServier Acquires Edgewise Muscular Dystrophy Business for Up to $2.65 Billi... Servier Acquires Edgewise Muscular Dystrophy Business for Up to $2.65 Billi... Read Post »
Clinical TrialsIdorsia Reports Positive High-Dose Phase 1 Data for C. difficile Vaccine Idorsia Reports Positive High-Dose Phase 1 Data for C. difficile Vaccine Read Post »
Clinical TrialsPersonalized mRNA Vaccine Plus KEYTRUDA Maintains Strong Melanoma Outcomes Personalized mRNA Vaccine Plus KEYTRUDA Maintains Strong Melanoma Outcomes Read Post »
Clinical TrialsIdorsia Unveils New Phase 3 Evidence for Aprocitentan’s Renal Benefits Idorsia Unveils New Phase 3 Evidence for Aprocitentan’s Renal Benefits Read Post »
Mergers & AcquisitionsAgios Lands Global Cevidoplenib Rights in Rare Hematology Push Agios Lands Global Cevidoplenib Rights in Rare Hematology Push Read Post »
Clinical TrialsNovartis Reports Strong Three-Year Scemblix Results in Newly Diagnosed CML Novartis Reports Strong Three-Year Scemblix Results in Newly Diagnosed CML Read Post »
New Drug ApprovalShionogi Wins FDA Approval for First Oral XOCOVA to Prevent COVID-19 After ... Shionogi Wins FDA Approval for First Oral XOCOVA to Prevent COVID-19 After ... Read Post »
Clinical TrialsBioNTech and BMS Report Strong Phase 2 Activity for Pumitamig in NSCLC BioNTech and BMS Report Strong Phase 2 Activity for Pumitamig in NSCLC Read Post »
Clinical TrialsReplimune’s RP2 Shows Durable Responses in Advanced Solid Tumors Replimune’s RP2 Shows Durable Responses in Advanced Solid Tumors Read Post »
Health TidingsUCB, Biogen Report Positive PHOENYCS GO Results in SLE UCB, Biogen Report Positive PHOENYCS GO Results in SLE Read Post »
Health TidingsPfizer’s BRAFTOVI Cuts Progression Risk by 56% in BRAF V600E mCRC Pfizer’s BRAFTOVI Cuts Progression Risk by 56% in BRAF V600E mCRC Read Post »
Health TidingsRevMed’s Daraxonrasib Cuts Death Risk by 60% in PDAC RevMed’s Daraxonrasib Cuts Death Risk by 60% in PDAC Read Post »
Clinical TrialsASCO 2026: Novartis’s New PSMAddition Analysis Supports Broad Pluvicto Us... ASCO 2026: Novartis’s New PSMAddition Analysis Supports Broad Pluvicto Us... Read Post »
Clinical TrialsLilly’s Retevmo Reduces Recurrence Risk by 83% in RET-Positive NSCLC Lilly’s Retevmo Reduces Recurrence Risk by 83% in RET-Positive NSCLC Read Post »
Clinical TrialsAkeso’s Ivonescimab Cuts Risk of Death by 34% in Phase 3 Squamous NSCLC T... Akeso’s Ivonescimab Cuts Risk of Death by 34% in Phase 3 Squamous NSCLC T... Read Post »
Clinical TrialsApalutamide Plus ADT Delivers Landmark Phase 3 Results in High‑Risk Local... Apalutamide Plus ADT Delivers Landmark Phase 3 Results in High‑Risk Local... Read Post »
Health TidingsIndustry Perspective: What Wockhardt’s ZAYNICH FDA Approval Means for Pat... Industry Perspective: What Wockhardt’s ZAYNICH FDA Approval Means for Pat... Read Post »
Health TidingsOtsuka Reports Positive Phase 3 Results of Centanafadine in Adult ADHD Ahea... Otsuka Reports Positive Phase 3 Results of Centanafadine in Adult ADHD Ahea... Read Post »
Clinical TrialsCogent’s PEAK Trial Shows Significant Survival Benefit in KIT-Driven GIST Cogent’s PEAK Trial Shows Significant Survival Benefit in KIT-Driven GIST Read Post »
Clinical TrialsIncyte’s frontMIND Trial Delivers Positive Phase 3 Results in High-Risk D... Incyte’s frontMIND Trial Delivers Positive Phase 3 Results in High-Risk D... Read Post »
Clinical TrialsPfizer’s TALAPRO-3 Trial Shows Strong Benefit for TALZENNA Plus XTAND... Pfizer’s TALAPRO-3 Trial Shows Strong Benefit for TALZENNA Plus XTAND... Read Post »
Clinical TrialsImmunome’s Varegacestat Cuts Risk of Desmoid Tumor Progression by 84% in ... Immunome’s Varegacestat Cuts Risk of Desmoid Tumor Progression by 84% in ... Read Post »
Clinical TrialsFirst-Line RYBREVANT Plus LAZCLUZE Shows Sustained Survival in Atypical EGF... First-Line RYBREVANT Plus LAZCLUZE Shows Sustained Survival in Atypical EGF... Read Post »
Health TidingsEU Expands Comirnaty Authorization for Children Under 5 EU Expands Comirnaty Authorization for Children Under 5 Read Post »
Health TidingsMHRA Approves Sanofi’s Rilzabrutinib for Adults with Chronic ITP MHRA Approves Sanofi’s Rilzabrutinib for Adults with Chronic ITP Read Post »
Health TidingsWHO Endorses Regeneron’s Maftivimab for Bundibugyo Ebola Trials WHO Endorses Regeneron’s Maftivimab for Bundibugyo Ebola Trials Read Post »
Health TidingsBMS’s Mezigdomide Hits Phase 3 Goal in Relapsed Myeloma BMS’s Mezigdomide Hits Phase 3 Goal in Relapsed Myeloma Read Post »
New Drug ApprovalFDA Approves First Inhaled Mealtime Insulin for Pediatric Diabetes FDA Approves First Inhaled Mealtime Insulin for Pediatric Diabetes Read Post »
Clinical TrialsDizal’s Sunvozertinib Outperforms Chemotherapy in WU-KONG28 Trial Dizal’s Sunvozertinib Outperforms Chemotherapy in WU-KONG28 Trial Read Post »
New Drug ApprovalFDA Approves Wockhardt’s ZAYNICH; India Also Grants Authorization FDA Approves Wockhardt’s ZAYNICH; India Also Grants Authorization Read Post »
Clinical TrialsPfizer Reports Landmark Seven-Year Results for LORBRENA in ALK-Positive NSC... Pfizer Reports Landmark Seven-Year Results for LORBRENA in ALK-Positive NSC... Read Post »
Clinical TrialsAstraZeneca’s Anselamimab Shows Survival Benefit in Kappa AL Amyloidosis,... AstraZeneca’s Anselamimab Shows Survival Benefit in Kappa AL Amyloidosis,... Read Post »
Health TidingsMerck Advances Calderasib With FDA Breakthrough Therapy Designation in Lung... Merck Advances Calderasib With FDA Breakthrough Therapy Designation in Lung... Read Post »
New Drug ApprovalEuropean Commission Authorizes New VENCLYXTO Regimens for CLL European Commission Authorizes New VENCLYXTO Regimens for CLL Read Post »
Health TidingsPhase 2b Failure Ends Agios’ Tebapivat Program in Lower-Risk MDS Phase 2b Failure Ends Agios’ Tebapivat Program in Lower-Risk MDS Read Post »
Clinical TrialsMajesTEC‑9 Confirms TECVAYLI Survival Benefit in Relapsed Multiple Myelom... MajesTEC‑9 Confirms TECVAYLI Survival Benefit in Relapsed Multiple Myelom... Read Post »
Health TidingsReplimune Aligns with FDA on RP1 Resubmission Path in Advanced Melanoma Replimune Aligns with FDA on RP1 Resubmission Path in Advanced Melanoma Read Post »
Health TidingsFDA Extends Review of Beren’s Adrabetadex NDA for Infantile-Onset NPC FDA Extends Review of Beren’s Adrabetadex NDA for Infantile-Onset NPC Read Post »
